Navigation Links
BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Date:5/8/2008

alleviation of symptoms are consistent with prior

Phase II study results of the 300mg dose of i.m. peramivir.

-- Reductions in viral shedding and percentage of patients shedding virus

were consistent with the data seen in our previous phase II study.

-- Pharmacokinetic data in the treated population indicate that patients

achieved consistent drug levels, which were similar to those seen in

our previous well-controlled Phase I trial.

BioCryst is continuing development of a more concentrated formulation and plans to test higher doses of i.m. peramivir in the next Phase II study. The doses to be studied in Phase II will be selected based on a planned mid 2008 analysis of the ongoing Phase I study of the more concentrated formulation.

"We are encouraged by the signs of activity of i.m. peramivir and are prepared to move forward and evaluate a higher dose. The consistency seen between the results of our recent clinical trials gives us confidence that i.m. peramivir has the potential to be an effective treatment for influenza," stated Dr. Thomas J. Simon, Interim Chief Medical Officer.

BCX-4208 development update

Following review of a planned interim analysis of the ongoing Phase IIa trial of BCX-4208 in psoriasis, Roche has terminated its license agreement for the development of BCX-4208 for autoimmune diseases and transplant. As a result, BioCryst will regain worldwide rights to BCX-4208. Roche and BioCryst have agreed to complete the ongoing Phase IIa trial. The planned interim analysis showed that BCX-4208 was safe and well-tolerated; clinical efficacy was not demonstrated.

The ongoing Phase IIa trial is a randomized, double blind, placebo controlled, dose ranging study in 66 patients with moderate to severe plaque psoriasis. BCX-4208 is administered once a day for 6 weeks at a dose of either 20mg or 120mg. The primary objectives of this study are to assess the safety, tolerability, an
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
2. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
3. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
4. BioCryst to Present at UBS 2007 Global Life Sciences Conference
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
7. Dendreon Reports First Quarter 2008 Financial Results
8. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Oncothyreon Reports First Quarter 2008 Financial Results
11. iCAD Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Theravalues Corporation est fier d,annoncer le lancement de ... Hi Europe 2014 (du 2 au 4 décembre à ... la plus biodisponible actuellement sur le marché, elle ... approuvés par les règlements européens. La ... racine de curcuma ( Curcuma longa ) qui ...
(Date:11/24/2014)... Nov. 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has submitted ... U.S. Food and Drug Administration (FDA), which brings the ... seven, with eighteen submissions now pending at the FDA. ... CEO of the Company, commented, "Our team here at ...
(Date:11/24/2014)... 2014   First ... Elsevier , a world-leading provider of scientific, ... announce the launch of the latest title in the ... in Food Science . ... a new platform to keep up-to-date with the expanding volume ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 2014 ... Dihydrazide Industry is a professional and in-depth research ... Adipic Dihydrazide information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3IGI Laboratories, Inc. Announces ANDA Submission 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3
... - Third Wave Technologies reported a smaller net ... 2006, but the company experienced impressive growth in clinical molecular ... Wave, which develops molecular diagnostic products for use in clinical ... net loss of $22.3 million, or 54 cents per share, ...
... Ken Rheingans' most immediate focus is next weekend's BarCamp ... BarCamp USA , the state's first national technology unconference. ... which will be held August 23-26 on the Jefferson County ... , said organizers would like to draw 5,000 technologists to ...
... this month's meeting of the Wisconsin Innovation Network ... Taxpayers Alliance was asked what single thing was standing ... the state average. , ,Berry, whose organization has been charting ... didn't give a predictable answer about high taxes. Instead, the ...
Cached Biology Technology:Third Wave reports net loss of $18.9M for 2006 2Wisconsin to host technology BarCamp USA 2Wisconsin to host technology BarCamp USA 3Education is fundamental to Milwaukee's growth 2Education is fundamental to Milwaukee's growth 3Education is fundamental to Milwaukee's growth 4
(Date:11/5/2014)... Rio de Janeiro, Brazil -Individuals show great diversity in ... importantly, males and females greatly differ in their perceptual ... kinds of smell tests. , Sex differences ... social behaviors and may be connected to one,s perception ... and emotions. Thus, women,s olfactory superiority has been suggested ...
(Date:11/4/2014)... School of Medicine announced today that it is ... by the Bill & Melinda Gates Foundation. ... and Reproductive Sciences; and Vice Chair of Research ... Medicine will pursue an innovative global health and ... Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds ...
(Date:11/4/2014)... OXFORD, England , November 4, 2014 ... expansion and vertical market growth   Fuel3D ... it has closed a funding round totaling $6.4 million (£4 ... (£1.6 million) funding secured earlier this year and paves the ... product in 2015. The funding round was led ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... the focus of the Society for Nutrition Education,s 2009 ... small step in fighting world hunger. Food security remains ... attention in order to combat the issues of poverty, ... Education (SNE) encourages its members and the public to ...
... SANTA CLARA, Calif., Oct. 9 Synaptics(R),Incorporated (Nasdaq: ... interface,solutions for mobile computing, communications, and entertainment devices,announced ... the first quarter,of fiscal 2009 on Thursday, October ... will host a corresponding conference call for analysts ...
... Researchers at the European Molecular Biology Laboratory (EMBL) have ... developmental blueprint of a vertebrate. With a newly developed ... cells for the first 24 hours in the life ... three-dimensional, digital representation of the embryo. The study, published ...
Cached Biology News:World Food Day brings attention to food security around the globe 2Synaptics to Report First Quarter Results on October 23 2Digital zebrafish embryo provides the first complete developmental blueprint of a vertebrate 2
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Yersinia pestis...
C/EBPdelta Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Adenylate kinase isoenzyme 6...
Biology Products: